임상용 Ga-68 표지 방사성의약품의 합성을 위한 자동합성장치 개발
Development of an Automated Synthesizer for the Routine Production of Ga-68 Radiopharmaceuticals
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
The germanium-68/gallium-68 (68Ge/68Ga) generator has high spatial utilization and requires little maintenance, making it economical and easy to produce. Thus, the frequency of use of 68Ga radiopharmaceuticals is rapidly increasing worldwide. Therefore, this study attempted to develop an automated synthesizer for the routine clinical application of 68Ga radiopharmaceuticals. The automated synthesizer was based on a fixed tubing system and the structure was designed after adjusting the position of the parts to reflect the synthesis method. Using various components that can be supplied in Korea, the automated synthesizer was manufactured at a much lower price cost than that of a commercialized automated synthesizer sold by companies. 68Ga-DOTA-[Tyr3]-octreotide (68Ga-DOTATOC) was synthesized to evaluate the performance of the automated synthesizer. 68Ga-DOTATOC could be synthesized with about 65% of non-decay corrected yield, and the synthesized 68Ga-DOTATOC met all quality control standards. We have synthesized 68Ga-DOTATOC more than 100 times, and only faced a few problems caused by mechanical errors. In this study, we successfully developed a simple automated synthesizer for 68Ga radiopharmaceuticals with high reproducibility. As various 68Ga radiopharmaceuticals have recently been developed, it is expected that the automated synthesizer developed in this study will be useful for routine clinical use.
Abstract
The germanium-68/gallium-68 (68Ge/68Ga) generator has high spatial utilization and requires little maintenance, making it economical and easy to produce. Thus, the frequency of use of 68Ga radiopharmaceuticals is rapidly increasing worldwide. Therefore, this study attempted to develop an automated synthesizer for the routine clinical application of 68Ga radiopharmaceuticals. The automated synthesizer was based on a fixed tubing system and the structure was designed after adjusting the position of the parts to reflect the synthesis method. Using various components that can be supplied in Korea, the automated synthesizer was manufactured at a much lower price cost than that of a commercialized automated synthesizer sold by companies. 68Ga-DOTA-[Tyr3]-octreotide (68Ga-DOTATOC) was synthesized to evaluate the performance of the automated synthesizer. 68Ga-DOTATOC could be synthesized with about 65% of non-decay corrected yield, and the synthesized 68Ga-DOTATOC met all quality control standards. We have synthesized 68Ga-DOTATOC more than 100 times, and only faced a few problems caused by mechanical errors. In this study, we successfully developed a simple automated synthesizer for 68Ga radiopharmaceuticals with high reproducibility. As various 68Ga radiopharmaceuticals have recently been developed, it is expected that the automated synthesizer developed in this study will be useful for routine clinical use.
참고문헌 (24)
- Pichler BJ, "Positron emission tomography", magnetic resonance imaging : the next generation of multimodality imaging?, 2008, pp.38, 199~208
- Spencer SS, "Clinical applications : MRI, SPECT, and PET", Magn Reson Imaging, 13, pp.1119~1124 (1995)[DOI]
- Filippou V, "Recent advances on the development of phantoms using 3D printing for imaging with CT, MRI, PET, SPECT, and ultrasound", Med Phys, 45, pp.e740~e760 (2018)[DOI]
- Voss SD, "SPECT", CT, PET, MRI : oncologic and infectious applications and protocol considerations, pp.Pediatr Radiol, 2023[DOI]
- Berger A, "How does it work? Positron emission tomography", BMJ, 326, pp.1449~ (2003)[DOI]
- Shukla AK, "Positron emission tomography : an overview", J Med Phys, 31, pp.13~21 (2006)[DOI]
- Mason C, "Novel tracers and radionuclides in PET imaging", Radiol Clin North Am, 59, pp.887~918 (2021)[DOI]
- Lau J, "Insight into the development of PET radiopharmaceuticals for oncology", Cancers(Basel), 12, pp.1312~ (2020)[DOI]
- Zhu J, "Development of amino acid-based radiopharmaceuticals for tumor imaging", Mini Rev Med Chem, 18, pp.561~583 (2018)[DOI]
- Lin M, "Monoclonal antibody based radiopharmaceuticals for imaging and therapy", Curr Probl Cancer, 45, pp.100796~ (2021)[DOI]
- Rong J, "Radiochemistry for positron emission tomography", Nat Commun, 14, pp.3257~ (2023)[DOI]
- Wang Y, "Production review of accelerator-based medical isotopes", Molecules, 27, pp.5294~ (2022)[DOI]
- Velikyan I, "Prospective of 68Ga-radiopharmaceutical development", Theranostics, 4, pp.47~80 (2013)[DOI]
- Zhernosekov KP, "Processing of generator-produced 68Ga for medical application", J Nucl Med, 48, pp.1741~1748 (2007)[DOI]
- Nelson BJB, "Good practices for 68Ga radiopharmaceutical production", EJNMMI Radiopharm Chem, 7, pp.27~ (2022)[DOI]
- Velikyan I, "68Ga-based radiopharmaceuticals : production and application relationship", Molecules, 20, pp.12913~12943 (2015)[DOI]
- Banerjee SR, "Clinical applications of Gallium-68", Appl Radiat Isot, 76, pp.2~13 (2013)[DOI]
- 강건욱, "췌장신경내분비종양에서 기능 영상과 펩타이드 수용체 방사성핵종 치료", 대한췌담도학회지, 26(1), pp.10~14 (2021), 대한췌장담도학회
- 홍정희, "전립선암에서 전립선특이막항원을 이용한 특정표적 진단치료법의 최신 지견", Journal of Urologic Oncology, 20(4), pp.207~222 (2022), 대한비뇨기종양학회[DOI]
- Dinesh Shetty, "68Ga-Labeled Radiopharmaceuticals for Positron Emission Tomography", Nuclear Medicine and Molecular Imaging, 44(4), pp.233~240 (2010), 대한핵의학회
- Lepareur N., "Cold kit labeling: the future of 68Ga radiopharmaceuticals?", Front Med (Lausanne), 9, pp.812050~ (2022)[DOI]
- Kumar K, "The current status of the production and supply of gallium-68", Cancer Biother Radiopharm, 35, pp.163~166 (2020)[DOI]
- Seemann J, "DATATOC: a novel conjugate for kit-type 68Ga labelling of TOC at ambient temperature", EJNMMI Radiopharm Chem, 1, pp.4~ (2018)[DOI]
- Elsinga P, "Radiopharmacy Committee of the EANM. Guidance on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals", Eur J Nucl Med Mol Imaging, 37, pp.1049~1062 (2010)[DOI]